BELLEVUE, Wash., June 25, 2012 /PRNewswire/ -- SCOLR Pharma, Inc. (PINK: SCLR) today launched a new website to support their CDT® (Controlled Delivery Technology) formulated vitamins, minerals and dietary supplements. The website, www.scolr.com, is part of SCOLR's initiative to provide consumer related education on the industry and how its CDT® based products enhance performance and provide value.
The website contains product information and consumer "touch-points," including a Q&A section to address frequently asked questions and a "blog" feature. In addition, the website will contain information on SCOLR's development activities on Over-the-counter (OTC) and prescription drug formulations. The company will continue to add new features to the website that may include coupons and rewards programs.
Stephen Turner, President and CEO of SCOLR, said: "SCOLR seeks to define 'value' as the ideal combination of safety, efficacy, convenience and cost. Our goal is to deliver the best overall experience to consumers shopping for value, by providing products with the optimal release of their active ingredients over time. Our new website provides us with an efficient vehicle to reach out and educate consumers. I am excited about our plans for this website, and how we will utilize it to support continued growth and awareness on CDT®. The closer we are to the consumer, the better we will be at meeting their needs."
About SCOLR Pharma:
Based in Bellevue, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT® platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Its CDT® drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call (425) 368-1050 or visit http://www.scolr.com/.
Forward looking statements:
Any statements made in this press release that relate to future plans, events or performance are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements include statements regarding the use of proceeds of a financing transaction, efforts to expand the number and type of nutritional products available to consumers, future profitability, and potential commercialization of SCOLR's Ibuprofen product. Factors that could cause these forward-looking statements to differ from actual results include adverse consumer or retailer reception of SCOLR's products, SCOLR's inability to source adequate inventory of its products in a timely matter and on favorable terms, any adjustments to the preliminary unaudited results presented herein, unfavorable regulatory determinations, competitive factors and other risks and uncertainties discussed in the company's periodic reports on Form 10-K and 10-Q and other filings with the Securities and Exchange Commission. SCOLR Pharma, Inc. undertakes no obligation to update or revise any forward-looking statements.
Contacts:
Investor Relations:
SCOLR Pharma, Inc.
425.368.1050
SOURCE SCOLR Pharma, Inc.
